Skip to main content
Clinical Trials/NCT06266520
NCT06266520
Recruiting
Not Applicable

Micro-needle-knife Therapy in Releasing the Superficial Fascia for Patients With Acute Ankle Sprain: an Assessor-blinded, Randomised Controlled Trial

Sen-wei Lu1 site in 1 country80 target enrollmentJanuary 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Ankle Sprain
Sponsor
Sen-wei Lu
Enrollment
80
Locations
1
Primary Endpoint
Visual Analogue Scale (VAS)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this type of randomized controlled trial, employing a blinded evaluator methodology, to verify the clinical efficacy and safety of MNK therapy. This aims to provide a reference for clinical practitioners and AAS patients in their decision-making process.

Participants will randomly allocated into two groups using a random number table method, with forty patients in each group. The experimental group (Group 1) underwent MNK therapy to release the superficial fascia, while the control group (Group 2) received conventional acupuncture treatment.

Registry
clinicaltrials.gov
Start Date
January 1, 2023
End Date
June 1, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sen-wei Lu
Responsible Party
Sponsor Investigator
Principal Investigator

Sen-wei Lu

Prof.

Affiliated Dongyang Hospital of Wenzhou Medical University

Eligibility Criteria

Inclusion Criteria

  • 16 to 55 years old
  • Clear history of trauma within 1 to 7 days
  • Presence of localized swelling, pain, bruising, and limping symptoms in the ankle joint
  • Pain in the ankle joint upon resistance
  • No accompanying fractures
  • Diagnosis of acute ankle injury according to the "Diagnostic and Therapeutic Criteria of Traditional Chinese Medicine"
  • No prior treatment before participating in this therapy
  • Willingness to participate in this study and signing of the informed consent form

Exclusion Criteria

  • Individuals with clear indications for surgery
  • Those suffering from gout, rheumatoid arthritis, joint tuberculosis, joint tumors, etc.
  • Pregnant or breastfeeding women
  • Individuals with serious primary diseases of the cardiovascular, liver, kidney, brain, and hematopoietic systems
  • Those with local skin lesions or skin diseases
  • Individuals with coagulation dysfunction
  • Those with severe fear of needles
  • Individuals unwilling to comply with the treatment regimen

Outcomes

Primary Outcomes

Visual Analogue Scale (VAS)

Time Frame: up to one mont

The VAS is utilized to assess the degree of pain experienced by the patient. Patients select an appropriate number (0 to 10) based on their perceived pain intensity: 0 indicates no pain and a normal state; 1 to 3 signifies mild pain that is tolerable and does not interfere with daily activities; 4 to 6 represents moderate pain that is noticeable and tolerable but affects daily life and sleep; 7 to 10 indicates severe pain that is intolerable.

Kofoed Ankle Score

Time Frame: up to one mont

This score evaluates the functional recovery of the ankle joint following treatment, focusing on pain, function, and mobility. The total score is out of 100, with 85-100 classified as excellent, 75-85 as good, 70-74 as satisfactory, and below 70 as poor.

Study Sites (1)

Loading locations...

Similar Trials